GHK Peptide Research: Carbonless Analogue Study Findings

A new computational study published in Physical Chemistry Chemical Physics (April 2026) is pushing the boundaries of peptide science in a direction few researchers have explored: what happens when you remove every carbon atom from a biologically relevant peptide? Skurski and Anusiewicz applied this provocative concept to the well-known tripeptide Gly-His-Lys — commonly referred to as GHK — creating a theoretical "carbonless" analogue and modeling its structural and metal-binding behavior. While the research is entirely computational at this stage, the findings open a genuinely novel conversation about how far biochemical design principles can be stretched, and what that might eventually mean for peptide therapeutics.

What This Study Found

The central premise of this research is a concept called carbonless biomolecular design. Under this framework, carbon atoms in a molecule are systematically replaced by pairs of boron (B) and nitrogen (N) atoms, a substitution strategy grounded in a chemistry principle known as isoelectronicity. Because a boron-nitrogen bond mimics the electron count of a carbon-carbon bond, the resulting molecules — at least in theory — can preserve much of the structural logic of their carbon-based counterparts while being chemically distinct.

The researchers selected glycine, histidine, and lysine as their model amino acids, along with the tripeptide GHK (Gly-His-Lys), which has been the subject of considerable scientific interest due to its role in copper binding and its naturally occurring presence in human plasma. Using advanced quantum chemical calculations — specifically DFT(ωB97XD)/aug-cc-pVDZ with aqueous solvation modeling — the team identified what they termed the lowest-energy carbonless analogues of each amino acid: cGly, cHis, and cLys. These were defined as the most stable isoelectronic boron-nitrogen constitutional isomers for each respective amino acid.

From these building blocks, the researchers constructed cGHK, the proposed carbonless analogue of the GHK tripeptide. Several notable findings emerged from the modeling:

1. Broader conformational landscape: The study suggests that cGHK displays a wider range of low-energy structural conformations than GHK under simulated physiological aqueous conditions. Researchers describe this as "enhanced conformational plasticity," meaning the carbonless molecule may be more structurally flexible than its natural counterpart. Whether this flexibility would translate into functional advantages or disadvantages in a biological system remains an open question requiring experimental validation.

2. Stronger copper(II) binding: One of the most striking computational findings concerns copper coordination. GHK is well-characterized for its ability to bind copper(II) ions, a property considered central to much of its studied biological activity. The researchers modeled copper binding using an experimentally supported motif involving three nitrogen atoms and one oxygen atom (3N1O), with one explicit water molecule included as a ligand. Using a thermodynamic calculation called an isodesmic ligand exchange cycle, the study found that cGHK showed stronger stabilization of copper(II) compared to GHK, with a calculated free energy of exchange (ΔGexch) of −6.24 kcal/mol at 298 K. This suggests the carbonless analogue may bind copper more tightly — though again, this is a computational prediction that has not yet been tested in laboratory or clinical settings.

Clinical Significance

It is essential to be clear: this study is entirely computational. No laboratory synthesis, cell-based experiments, animal studies, or human trials have been conducted on cGHK. The molecules described exist, at this point, only as mathematical models. Human data is not yet available, and substantial experimental work would be required before any clinical relevance could be assessed.

That said, the theoretical implications are worth understanding in context. GHK-Cu — the copper-bound form of the naturally occurring GHK tripeptide — has been studied in numerous preclinical and some clinical contexts, with researchers investigating its potential roles in wound healing, skin remodeling, anti-inflammatory signaling, and tissue repair. The copper-binding capacity of GHK is considered a key mechanistic feature in much of this research.

If a carbonless analogue like cGHK were ever to be synthesized and proven stable in biological environments, the finding of potentially stronger copper binding could theoretically be of interest to researchers studying metal coordination in peptide biology. However, stronger metal binding is not inherently better — it could alter biodistribution, toxicity profiles, or receptor interactions in unpredictable ways. These are questions that can only be answered through rigorous experimental science.

The broader significance of this study may lie less in cGHK specifically and more in the proof of concept it offers: that carbonless peptide analogues are computationally feasible, that BN substitution can meaningfully alter conformational behavior and metal binding thermodynamics, and that this design strategy could eventually become a tool in the medicinal chemist's toolkit for creating novel bioinspired scaffolds.

Current Access and Compliance Context

GHK-Cu peptide, the natural copper-bound tripeptide on which this research is conceptually based, is currently available in various topical formulations and has been studied in research contexts. It is not approved by the U.S. Food and Drug Administration (FDA) as a drug for any indication. In the United States, peptides including GHK-Cu exist in a complex and evolving regulatory landscape. As of 2024, the FDA has taken steps to restrict the compounding of certain peptides, and patients and practitioners should remain informed about current regulatory guidance.

The carbonless analogue cGHK described in this study is not a compound that exists in any commercial, compounded, or research-accessible form at this time. It is a theoretical molecule. Any future development would require synthesis, safety evaluation, and regulatory review before it could be considered for any human application.

Practitioners and patients interested in GHK-Cu or related peptides should work exclusively with licensed physicians who are knowledgeable about current FDA regulations, compounding pharmacy compliance, and the state of the evidence base.

What Patients Should Know

If you have encountered information about GHK peptide or copper peptides and are wondering whether this new research changes anything for your health decisions, here is a straightforward summary:

This study does not describe a new treatment. The carbonless GHK analogue exists only in theoretical form. No one can prescribe, compound, or administer cGHK — it has never been synthesized.

Computational chemistry is important foundational science. Studies like this one help researchers understand molecular behavior before investing in expensive laboratory or clinical work. They are a necessary early step in a very long road toward any potential application.

Existing GHK-Cu research has a separate evidence base. If you are interested in what science currently says about the naturally occurring GHK-Cu peptide, speak with a knowledgeable physician who can help you interpret the existing literature in the context of your individual health situation.

Ask questions about the source and regulatory status of any peptide product or therapy you are considering. Reputable practitioners will be transparent about what is known, what is unknown, and what is legally permissible.

Conclusion

The computational research by Skurski and Anusiewicz represents a genuinely creative leap in peptide science — one that asks what biomolecular design might look like if we stepped entirely outside the carbon framework that defines all known life. The study suggests that carbonless analogues of amino acids and peptides like GHK are theoretically feasible, and that BN substitution may tune both structural flexibility and metal-binding strength in meaningful ways. However, this work is firmly in the realm of theoretical chemistry, and translating these findings into any form of biological or clinical relevance would require years of additional research.

For patients and practitioners, the most prudent takeaway is this: science is always moving forward, sometimes in unexpected directions, and staying informed through credible, evidence-based sources is essential. If you are interested in peptide therapies and want guidance grounded in current evidence and regulatory reality, connect with a qualified physician through the Peptide Association's physician directory.

Find a knowledgeable peptide medicine practitioner near you at peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The research described is computational in nature; no clinical conclusions should be drawn. Always consult a licensed healthcare provider before making any decisions related to your health or any therapeutic interventions.

---

Citation (AMA format): Skurski P, Anusiewicz I. Carbonless amino acids and a carbonless GHK peptide. Phys Chem Chem Phys. 2026. doi:10.1039/d6cp00567e. PMID: 41859865.